Difference between revisions of "Thrombocytopenia in liver disease"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
| − | == | + | {| class="wikitable" style="text-align:center; width:100%;" |
| − | + | !colspan="4" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Section editors''' | |
| − | <big> | + | |- |
| + | |style="background-color:#F0F0F0; width:15%"|[[File:Shruti.jpg|frameless|upright=0.3|center]] | ||
| + | |style="width:35%"|<big>[[User:Shrutichaturvedi|Shruti Chaturvedi, MBBS, MSCI]]<br>Baltimore, MD</big><br>[https://www.linkedin.com/in/shruti-chaturvedi-bb83b126/ LinkedIn] | ||
| + | |style="background-color:#F0F0F0; width:15%"|[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]] | ||
| + | |style="width:35%"|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Nashville, TN</big> | ||
| + | |- | ||
| + | |} | ||
| + | See the [[Thrombocytopenia|thrombocytopenia reference page]] for general definitions and workup recommendations. | ||
| + | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
| + | |- | ||
| + | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> | ||
| + | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | ||
| + | |} | ||
| + | {{TOC limit|limit=3}} | ||
| + | =Thrombocytopenia in liver disease with planned procedure= | ||
| + | ==Avatrombopag monotherapy {{#subobject:7c8c62|Regimen=1}}== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
| + | ===Regimen {{#subobject:666055|Variant=1}}=== | ||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- | ||
| Line 11: | Line 31: | ||
| ADAPT-2 || Phase III || Placebo || Superior RR | | ADAPT-2 || Phase III || Placebo || Superior RR | ||
|} | |} | ||
| + | ====Therapy==== | ||
| + | *[[Avatrombopag (Doptelet)]] as follows: | ||
| + | **Platelet count less than 40 x 10<sup>9</sup>/L: 60 mg PO once per day on days 1 to 5 | ||
| + | **Platelet count at least 40 and less than 50 x 10<sup>9</sup>/L: 40 mg PO once per day on days 1 to 5 | ||
| − | ''' | + | '''Procedure days were days 10 to 13''' |
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | [[Category:Thrombocytopenia in liver disease regimens]] | |
| + | [[Category:Disease-specific pages]] | ||
| + | [[Category:Cytopenias]] | ||
Revision as of 13:42, 23 May 2018
| Section editors | |||
|---|---|---|---|
 |
Shruti Chaturvedi, MBBS, MSCI Baltimore, MD |
 |
Benjamin Tillman, MD Nashville, TN |
See the thrombocytopenia reference page for general definitions and workup recommendations.
2 regimens on this page
2 variants on this page
|
Thrombocytopenia in liver disease with planned procedure
Avatrombopag monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| ADAPT-1 | Phase III | Placebo | Superior RR |
| ADAPT-2 | Phase III | Placebo | Superior RR |
Therapy
- Avatrombopag (Doptelet) as follows:
- Platelet count less than 40 x 109/L: 60 mg PO once per day on days 1 to 5
- Platelet count at least 40 and less than 50 x 109/L: 40 mg PO once per day on days 1 to 5
Procedure days were days 10 to 13